+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Hemophilia Treatment Market Research Report by Product Type, Disease Indication, Distribution, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 120 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5122838
UP TO OFF until Dec 31st 2022
The United States Hemophilia Treatment Market size was estimated at USD 2,582.25 million in 2021, USD 2,882.50 million in 2022, and is projected to grow at a CAGR 8.14% to reach USD 4,131.11 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Hemophilia Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Product Type, the market was studied across Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.
  • Based on Disease Indication, the market was studied across Hemophilia A, Hemophilia B, and Polyethylene.
  • Based on Distribution, the market was studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Hemophilia Treatment market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hemophilia Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Hemophilia Treatment Market, including Baxter International, Inc., Bayer AG, Biogen Inc., Biotest AG, Chugai Pharmaceutical Co., Ltd., CSL Ltd., Genentech, Inc., Grifols S.A., Kedrion Biopharma Inc., Novo Nordisk A/S, Octapharma AG, Pfizer, Inc., Shire Plc, Spark Therapeutics, Inc., and Swedish Orphan Biovitrum AB.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Hemophilia Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Hemophilia Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Hemophilia Treatment Market?
4. What is the competitive strategic window for opportunities in the United States Hemophilia Treatment Market?
5. What are the technology trends and regulatory frameworks in the United States Hemophilia Treatment Market?
6. What is the market share of the leading vendors in the United States Hemophilia Treatment Market?
7. What modes and strategic moves are considered suitable for entering the United States Hemophilia Treatment Market?
Frequently Asked Questions about the U.S. Hemophilia Treatment Market

What is the estimated value of the U.S. Hemophilia Treatment Market?

The U.S. Hemophilia Treatment Market was estimated to be valued at $2582.25 Million in 2021.

What is the growth rate of the U.S. Hemophilia Treatment Market?

The growth rate of the U.S. Hemophilia Treatment Market is 8.1%, with an estimated value of $4131.11 Million by 2027.

What is the forecasted size of the U.S. Hemophilia Treatment Market?

The U.S. Hemophilia Treatment Market is estimated to be worth $4131.11 Million by 2027.

Who are the key companies in the U.S. Hemophilia Treatment Market?

Key companies in the U.S. Hemophilia Treatment Market include Baxter International, Inc., Bayer AG, Biogen Inc., Biotest AG, Chugai Pharmaceutical Co., Ltd., CSL Ltd., Genentech, Inc., Grifols S.A. and Novo Nordisk A/S.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Hemophilia Treatment Market, by Product Type
6.1. Introduction
6.2. Antifibrinolytic Agents
6.3. Desmopressin
6.4. Plasma Derived Coagulation Factor Concentrates
6.5. Recombinant Coagulation Factor Concentrates
7. Hemophilia Treatment Market, by Disease Indication
7.1. Introduction
7.2. Hemophilia A
7.3. Hemophilia B
7.4. Polyethylene
8. Hemophilia Treatment Market, by Distribution
8.1. Introduction
8.2. E-commerce
8.3. Hospital Pharmacies
8.4. Retail Pharmacies
9. California Hemophilia Treatment Market10. Florida Hemophilia Treatment Market11. Illinois Hemophilia Treatment Market12. New York Hemophilia Treatment Market13. Ohio Hemophilia Treatment Market14. Pennsylvania Hemophilia Treatment Market15. Texas Hemophilia Treatment Market
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Baxter International, Inc.
17.2. Bayer AG
17.3. Biogen Inc.
17.4. Biotest AG
17.5. Chugai Pharmaceutical Co., Ltd.
17.6. CSL Ltd.
17.7. Genentech, Inc.
17.8. Grifols S.A.
17.9. Kedrion Biopharma Inc.
17.10. Novo Nordisk A/S
17.11. Octapharma AG
17.12. Pfizer, Inc.
17.13. Shire Plc
17.14. Spark Therapeutics, Inc.
17.15. Swedish Orphan Biovitrum AB
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES HEMOPHILIA TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES HEMOPHILIA TREATMENT MARKET DYNAMICS
FIGURE 8. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2027
FIGURE 11. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTIC AGENTS, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTIC AGENTS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DESMOPRESSIN, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2021 VS 2027 (%)
FIGURE 20. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2021 VS 2027 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2027
FIGURE 22. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA A, 2019-2027 (USD MILLION)
FIGURE 23. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA B, 2019-2027 (USD MILLION)
FIGURE 25. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 26. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY POLYETHYLENE, 2019-2027 (USD MILLION)
FIGURE 27. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY POLYETHYLENE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 28. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (%)
FIGURE 29. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (USD MILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2027
FIGURE 31. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY E-COMMERCE, 2019-2027 (USD MILLION)
FIGURE 32. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY E-COMMERCE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 33. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 34. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 35. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 36. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 37. CALIFORNIA HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. FLORIDA HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. ILLINOIS HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. NEW YORK HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. OHIO HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. PENNSYLVANIA HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. TEXAS HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. UNITED STATES HEMOPHILIA TREATMENT MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 45. UNITED STATES HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 46. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES HEMOPHILIA TREATMENT MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTIC AGENTS, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY POLYETHYLENE, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY E-COMMERCE, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. CALIFORNIA HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 19. CALIFORNIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 20. CALIFORNIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 21. CALIFORNIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 22. FLORIDA HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 23. FLORIDA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 24. FLORIDA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 25. FLORIDA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 26. ILLINOIS HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 27. ILLINOIS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 28. ILLINOIS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 29. ILLINOIS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 30. NEW YORK HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 31. NEW YORK HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 32. NEW YORK HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 33. NEW YORK HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 34. OHIO HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 35. OHIO HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 36. OHIO HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 37. OHIO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 38. PENNSYLVANIA HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 39. PENNSYLVANIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 40. PENNSYLVANIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 41. PENNSYLVANIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 42. TEXAS HEMOPHILIA TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 43. TEXAS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2019-2027 (USD MILLION)
TABLE 44. TEXAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2019-2027 (USD MILLION)
TABLE 45. TEXAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 46. UNITED STATES HEMOPHILIA TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 47. UNITED STATES HEMOPHILIA TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 48. UNITED STATES HEMOPHILIA TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 49. UNITED STATES HEMOPHILIA TREATMENT MARKET RANKING
TABLE 50. UNITED STATES HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
TABLE 51. UNITED STATES HEMOPHILIA TREATMENT MARKET MERGER & ACQUISITION
TABLE 52. UNITED STATES HEMOPHILIA TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 53. UNITED STATES HEMOPHILIA TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 54. UNITED STATES HEMOPHILIA TREATMENT MARKET INVESTMENT & FUNDING
TABLE 55. UNITED STATES HEMOPHILIA TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 56. UNITED STATES HEMOPHILIA TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • Baxter International, Inc.
  • Bayer AG
  • Biogen Inc.
  • Biotest AG
  • Chugai Pharmaceutical Co., Ltd.
  • CSL Ltd.
  • Genentech, Inc.
  • Grifols S.A.
  • Kedrion Biopharma Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer, Inc.
  • Shire Plc
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB

Methodology

Loading
LOADING...